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ZOLLINGER (1953) and Tonz (1957) described the induction of kidney tumours
in rats by the repeated parenteral injection of lead phosphate. This finding was
confirmed by Walpole (see Matthews and Walpole, 1958). Fairhall and Miller
(1941) reported kidney changes (enlargment of cells, vesiculation of nuclei, and
accumulation of brown granules) but no tumours, in rats fed diets containing
0-1 per cent lead arsenate or 0 I per cent lead carbonate for two years. Boyland,
Dukes, Grover and Mitchley (1962) reported the induction of cuboidal cell carci-
nomas in rats fed a diet containing 1 per cent wt/wt (dry diet) lead acetate: 15
out of 16 rats which survived for 331 days or more, up to 629 days, developed
single or multiple kidney tumours. Because it was known that lead compounds
cause increased secretion of porphyrins, another compound, namely sedormid,
having the same effect was administered in the diet to a second group of rats.
The only kidney tumour recorded in this group, 17 of which survived for more
than 300 days, was a small transitional-cell carcinoma of the renal pelvis. van
Esch, van Genderen and Vink (1962) also induced renal tumours in rats of both
sexes by feeding lead acetate. Thirteen out of 24 rats given 1 0 per cent, and 11
out of 32 given 0.1 per cent lead acetate in the diet developed renal neoplasms.
Testosterone has been shown to have a renotropic effect by several workers
(Selye, 1939; Thorn and Engel, 1938; Korenchevsky and Hall, 1939). Roe and
Mitchley, (1962) reported that in female CBA mice, the administration of 1 mg.
testosterone once weekly for 30 weeks caused (a) a reduction in body weight, (b)
an increase in the kidney weight/body weight, kidney weight/liver weight, and
kidney weight/heart + lung weight ratios up to, or above, the values normally
found in male CBA mice. Klopp, Young and Taylor (1945) investigated, with
negative result, the possibility that testosterone might benefit patients with
renal failure.
Haddow (1954) reported that a single intraperitoneal injection of 10 mg.
xanthopterin given to rats weighing about 150 g. gave rise to a dramatic increase
in kidney size, accompanied by an outburst of mitotic activity in the renal
tubules. Subsequently the same effect of xanthopterin was observed in mice,
guinea-pigs, rabbits and hamsters.
The purpose of the experiment described in the present paper was to see
whether the administration of testosterone or of xanthopterin to rats would
influence renal carcinogenesis by lead.
MATERIALS AND METHODS
Two hundred male albino rats of the Chester Beatty strain were divided
randomly into 10 groups (A-K) of 24 or 16 rats as shown in Table I. ThroughoutLEAD INDUCED RENAL NEOPLASMS
TABLE I.-Detai8 of Treatment
Tre
Lead phosphate (once
Number weekly in 0 5 ml.
Group of rats water)
A . 24 . 4 s.c. injections 25
mg., 7 i.p. injections
25 mg., no treat-
ment for 9 weeks,
then 14 i.p. injec-
tions 12-5 mg.
[Total dose of lead
phosphate = 450
mg. per rat]
B . 24 . 4 s.c. injections 5 mg.,
7 i.p. injections 5
mg., no treatment
for 3 weeks, 4 i.p.
injections 5 mg., no
treatment for 2
weeks, then 14 i.p.
injections 5 mg.
[Total dose of lead
phosphate = 145
mg. per rat]
C . 24 . As in Group B except
only 1 mg. lead
phosphate given at
each injection.
[Total dose = 29 mg.
per rat]
D . 16 . As in Group C
E 16 As in Group C
F
G
H
J
K
16
16
16
24
24
. As in Group B
. As in Group B
None
None
None
eatment
Testosterone
propionate
(once weekly,
0-15 to 0-6 ml.
per injection,
starting 2
weeks before
the first injec-
tion of lead)
None
None
None
13 s.c. injections
50 mg./kg.
body weight,
no treatment
for 3 weeks, 4 s.c.
injections 25mg)
kg. no treat-
ment for 2
weeks, then 14
injections 50
mg/kg.
None
As in Group D
None
None
As in Group D
None
Xanthopterin
(once weekly in
arachis oil, 0-15
to 0-6 ml. per
injection, start-
ing 2 weeks
befor the first
injection of
lead)
None
None
None
None
13 s.c. injections
25 mg./kg.
body weight,
no treatment
for 3 weeks, 4
injections 12-5
mg./kg.
None
As in Group E
As in Group E
None
None
Summary of
treatment as
shown in
subsequent
tables
L+++
L+T
L+X
L++T
L++X
x
T
None
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the experiment they were kept in metal boxes and fed cubed diet 86 (J. C. Wither
& Co., 66, High Street, Godalming, Surrey) and water ad libitum.
Animals were killed when they developed obvious neoplasms, or were sick,
and examined thoroughly post mortem. Tissue was taken routinely from both
kidneys and from all suspected neoplasms for microscopic examination.
Details of treatment are shown in Table I. The lead phosphate used in this
experiment was of the technical grade of lead ortho-phosphate, supplied by
British Drug Houses; xanthopterin was kindly given to us by Professor A.
Albert, of Canberra, Australia; and testosterone propionate was of B.P. speci-
fication and prepared by Weddel Pharmaceuticals (Batch 18) in suspension form,
50 mg./ml.
The vehicle for xanthopterin was arachis oil and, for lead phosphate, distilled
water. Testosterone propionate was administered in the form supplied by the
manufacturer without dilution.
At first, all treatments were given by subcutaneous injection. Later (see
Table I) lead and xanthopterin were given by the intraperitoneal route because of
inflammation of the body wall.
RESULTS
Kidney tumours
Kidney tumours arose in altogether 34 rats of Groups A, B, F, G and K.
Details oftheir incidence and time ofappearance are shown in Table II and Fig. 1.
Malignant tumours were present in 16 rats and distant metastases in two. The
tumours were multiple in 21 of the 30 animals. The majority of tumours were
cuboidal-cell, tubular or papillary, adenomas or adenocarcinomas arising in the
renal cortex. Tumours of these types were present in 30 rats. Undifferentiated
malignant tumours were seen in a further 3 rats, including one of the untreated
controls (Group K). Another control rat developed a transitional-cell carcinoma
TABLE II.-Incidence ofKidney Tumours
Survi- Total rats Rats with Rats with
vors at which devel- adenomas Rats with Rats with other more than a
Treat- 200 oped kidney or adeno- adeno- types of kidney singlerenal
Group ment days tumours carcinomas carcinomas tumour tumour
A L+++ 3 2 2 0 0 1
B L++ 23 14 13 6 1 8
(Undifferentiated
malignant tumour)
C L+ 23 0 0 0 0 0
D L+T 15 0 0 0 0 0
E L+X 15 0 0 0 0 0
F L++T 14 9 8 3 1 7
(2 with distant (Undifferentiated
metastases) malignant tumour)
G L++X 16 7 7 3 0 5
H X 15 0 0 0 0 0
J T 24 0 0 0 0 0
K None 24 2 0 0 2 0
(1 Undifferentiated
malignant tumour
and 1 transitional
cell carcinoma
arising in renal
pelvis)LEAD INDUCED RENAL NEOPLASMS 863
GOPTREATMENT TIME OF DEATH IN DAYS
GROUP i(see Table I) 0-100 101-200 201-300 301-400 401-500 501-600 601-700
00000
A [ ++ ggggg 00 00 0 0000 000~ ~~~00
0 10 0 SOOW meoonu o B 0 0
0
C L 0 00 0000 g00 gggg .~~~~~~~~
D L T 0 00 000 0 ggg0 00
LX 0 0000 0000 0000 E L X o ooo__ 00 0 _ -_
F 0 LT °° ofoe o *oo |G LIL+X
E t 0n° °n 0 E) 00n H X o ~~~o~oo cioooooou ~00
____
H x 0 ~~~00
00 0000 0000 0
00
____ T ~ ~ ~~~~~~000000gg g00 ggg0
4K None 00 00 Oro gggnt 0000
0
FiG. 1. Renal tumours in relation to time of death.
0 No kidney tumour
e Benign adenomas only
* One or more adenocarcinomas
(3 Malignant tumour with distant metastasis
* Undifferentiated tumour
t Transitional cell carcinoma.
arising in the renal pelvis. Apart from these 2 control rats kidney tumours were
only seen in rats given injections of lead phosphate at the two higher dose levels
(L+++ and L++). No kidney tumours developed in groups given the lowest dose
oflead phosphate (L+), either alone (Group C) or in combination with testosterone
or xanthopterin (Groups D and E). Similarly, none arose in response to tes-
tosterone alone or xanthopterin alone.
There was no evidence that testosterone or xanthopterin either increased or
'reduced the carcinogenic effect of the intermediate dose of lead phosphate on the
kidney (c.f. Groups B, F and G).
One of the two neoplasms seen in the control group, i.e. the transitional cell
carcinoma, was clearly of a different histological type from all the other tumours.
The fact that one undifferentiated carcinoma of the renal cortex occurred in an
animal which received no treatment may be taken as an indication that a low
incidence of this type of tumour is to be expected as a " spontaneous " event in
the strain ofrats used for the experiment.
The distinction between benign renal tumours and malignant renal tumours
was not clear-cut except where distant metastases were present. Tumours
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and surrounding kidney tissue. Compression of surrounding tissues was fre-
quently present in such cases. Infiltration of suxrounding kidney tissue was
accepted as a criterion of malignancy. Invasive tumours often showed addi-
tionally areas of poor differentiation or pleomorphism and frequent mitoses.
However, the presence of frequent mitosis alone was not taken as indicating
malignancy.
Renal disease other than neoplasia
Chronic nephritis of the type which gives rise to widespread distension of the
renal tubules by eosinophilic hyaline material was present in almost all the rats
of all groups. None of the treatments appeared to affect the severity of the
condition (Table III) and it is notable that there was no obvious relation
between its severity and tumour development in Groups B, F and G.
TABLE III.-Relation Between Chronic Nephritis and Renal Neoplasia in
Rats Killed Between 401 and 500 Days*
Severity of Severity of Severity of neph-
No. of nephritis in nephritis in ritis in rela-
Treat- rats killed rats without rats with tion to treatment
ment between kidney tumours kidney tumours with lead
(See 401 and ,
Group Table I) 500 days Severe Mild Severe Mild Severe Mild
A L+++ 1 0 0 1 0
B L++ 13 3 2 4 4
C L+ 6 4 2 0 0
D L+T 1 0 1 0 0 F Treated with 28 12
E L+X 5 5 0 0 0 | lead
F L++T 8 1 1 4 2
G L++X 6 3 0 3 0
H T 8 6 2 0 0 Not treated 13 6
K None 7 4 2 0 1 S withlead
* The severity of the chronic nephritic condition was assessed as follows: Sections taken from
kidneys of all rats killed between 401 and 500 days were put in random order. The chronic nephritic
condition was then graded as " mild " or " severe " by one of us (F.J.C.R.) without knowledge of
from which group the sections were derived. The condition was regarded as "mild " if tubular
cysts and casts were few and there was no generalised enlargment of the kidnev. All other cases
were regarded as " severe ". No unaffected kidneys were encountered.
In addition to the condition of chronic nephritis, which was common to all
groups, all the kidneys from rats treated with xanthopterin contained crystalline
deposits which were thought to be xanthopterin itself. These deposits were both
within and between cells of the renal tubules. Their presence appeared to give
rise to no inflammatory response and had no obvious effect either on the severity
of the chronic nephritis or on the induction of renal tumours.
Incidence ofnon-renal tumours
This is shown in Table IV. Exposure to lead was not obviously associated
with the development oftumours other than ofthe kidney.
DISCUSSION
Clearly the results of the experiment were essentially negative. Xanthop-
terin, in doses sufficient to give rise to crystalline deposits in the kidneys, did notLEAD INDUCED RENAL NEOPLASMS
TABLE IV.-Primary Non-renal Neoplasms
Group
A
Treatment
L+++
No. of
rats in
group
24
No. of rats
with non-
renal
neoplasms
0
Details of neoplasms
B L++ 24 1 Multiple papillomata and transitional-
cell carcinoma of bladder
C L+ 24 4 1-Adenocarcinoma of pancreas
3-Localized lymphocytic neoplasm
(all arising in lung)
D L+T 16 3 1-Anaplastic carcinoma of prostate
1-Haemangioma of mesenteric lymph-
node
1-Myxomatous tumour of body wall
E L+X 16 2 1-Spindle-cell sarcoma arising in pelvis
1-Undifferentiated malignant tumour
arising in neck
F L++T 16 3 1-Adenoma of lung
1-Subcutaneous pleomorphic sarcoma
1-Localized lymphocytic neoplasm aris-
ing in lung
G L++X 16 1 Multiple papillomata of bladder
H x
5S
16 0
J T 94 2 1-Lymphosarcoma arising in wall of
descending colon with metastases in
mesenteric nodes
1-Large subcutaneous fibroma
K None 24 4 1-Localized lymphocytic neoplasm arising
in wall ofcaecum
2-Malignant lymphoma arising in thy-
mus
1-Exocrine adenoma of the pancreas
Day of death
ofrats with
neoplasms
441
510
23, 532 and 566
320
483
631
225
274
99
523
631
434
509
631
357
510 and 615
540
increase or decrease the incidence of renal tumours attributable to lead; and
-testosterone in high dose was similarly without effect.
Since chronic nephritis was present in all the rats in the experiment it is not
possible to say whether its presence was necessary for tumour induction. How-
ever, this seems unlikely in so far as the severity of the nephritic condition bore
no relation to the tumour response: kidneys showing severe nephritis had no
tumours, despite exposure to lead, whilst tumours were present in kidneys only
slightly affected by chronic nephritis. van Esch et al. (1962) in discussing the
relationship between chronic nephritis and renal tumours, implied that lead
administration gives rise to both lesions. Unfortunately, they do not give details
of the occurrence of chronic nephritis in their control animals.
It is interesting that, at the lowest level of administration, lead phosphate
injections gave rise to no renal neoplasms (Groups C, D and E). This suggests
that, for practical purposes anyway, there is a threshold dose level (between 29
and 145 mg. lead phosphate per rat in the present experiment) below which renal
-tumours are not induced.
In a follow-up study of 425 pensioners who had been previously exposed to
lead in an accumulator factory Dingwall-Fordyce and Lane (1963) found "no
evidence to suggest that malignant disease was associated with lead absorption ".
There was an increase in the incidence of cerebrovascular catastrophies. The
present experiments show that a large dose of lead is necessary to induce kidney
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tumours in rats. The amount of lead absorbed by the lead-workers covered in
Dingwall-Fordyce and Lane's survey might well have been too low to be carcino-
genic.
SUMMARY
1. Three groups of 24 male CB Wistar rats were injected with lead phosphate
repeatedly over a period of 34 weeks. The first group received a total dose of
450 mg. per rat; the second group, 145 mg. per rat; and the third, 29 mg. per
rat. More than haifthe rats in the first two groups which survived for more than
200 days developed benign or malignant kidney tumours. No renal tumours
developed in the third group.
2. Repeated injections of testosterone propionate or of xanthopterin failed to
influence the induction ofrenal tumours by lead.
3. All the rats in the experiment, including untreated controls, suffered mildly
or severely from chronic nephritis. The administration of lead, xanthopterin or
testosterone had no obvious effect on the severity of the renal disease, and the
severity ofthe disease was not obviously associated with tumour development.
4. Primary neoplasms of sites other than the kidney arose in approximately
equal frequency in all groups, andthere was no indication that any ofthe chemical
agents influenced their occurrence.
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